Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

Pancreatic cancer is an increasingly common cause of cancer mortality with a tight
correspondence between disease mortality and incidence. Furthermore, it is usually …

Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …

The desmoplastic stroma in solid tumors presents a formidable challenge to
immunotherapies that rely on endogenous or adoptively transferred T cells, however, the …

Pancreatic cancer is the deadliest disease, with a five-year overall survival rate of just 11%.
The pancreatic cancer patients diagnosed with early screening have a median overall …

Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is
characterized by poor treatment response and low survival time. The current clinical …

Pancreatic cancer is one of the most malignant tumors with increased incidence rate. The
effect of surgery combined with chemoradiotherapy on survival of patients is unsatisfactory …

Simple Summary Pancreatic ductal adenocarcinoma is a leading cause of cancer death
worldwide. Due to the frequently late diagnosis, early metastasis and high therapy …

Ubiquitination-related genes (URGs) exerted a crucial part in a variety of human disease
disorders; however, their association with pancreatic adenocarcinoma (PAAD) had yet to be …

Defining reliable surrogate markers and overcoming drug resistance are the most
challenging issues for improving therapeutic outcomes of antiangiogenic drugs (AADs) in …